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Synergistic Effect of Nogo-Neutralizing Antibody IN-1 and
Ciliary Neurotrophic Factor on Axonal Regeneration in 
Adult Rodent Visual Systems
QI CUI,1,2 KIN-SANG CHO,2,3 KWOK-FAI SO,2 and HENRY K. YIP2
ABSTRACT
The presence of Nogo axon regeneration inhibitory molecules in the central nervous system (CNS)
and the counteracting effect of IN-1 antibodies have been widely reported. In this study, we exam-
ined the effect of IN-1–producing hybridoma cells on axon regeneration in adult rodent retinal gan-
glion cells (RGCs) after various types of optic nerve (ON) injury, evaluating therein whether ciliary
neurotrophic factor (CNTF) potentiated the effect of IN-1. We found that application of IN-1 alone
failed to enhance regeneration of intracranially or intraorbitally transected RGC axons in a pe-
ripheral nerve (PN) graft. IN-1 hybridoma cells also failed to significantly promote intraorbitally
crushed ON axons to reenter the distal part of the ON. However, a combined application of IN-1
and CNTF had a synergistic effect in both intracranial PN and intraorbital ON crush paradigms.
This study suggests that the action of IN-1 antibodies in promoting axon regeneration in the CNS
could be more effective when coupled with other appropriate factors.
Key words: axon regeneration; ciliary neurotrophic factor; IN-1; Nogo; optic nerve injury; peripheral
nerve graft
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INTRODUCTION
THE PRESENCE of various axon regeneration inhibitorymolecules (Nogo, MAG, and OMgp) in the myelin
and oligodendrocytes of the central nervous system
(CNS) has been well documented over the past 15 years
(Caroni and Schwab, 1988; McKerracher et al., 1994;
Mukhopadhyay et al., 1994; Kottis et al., 2002). Three
different isoforms of Nogo have been cloned (Nogo-A,
Nogo-B, and Nogo-C), with identification of two in-
hibitory domains (Nogo-66 and Amino-Nogo) in Nogo
A (Chen et al., 2000; GrandPre et al., 2000; Fournier et
al., 2001). The effect of IN-1 antibodies, which are raised
in hybridoma cells and shown to block Nogo-A mole-
cules, has been studied with some success in the CNS,
particularly in the repair of adult spinal cord (Bregman
et al., 1995; Z’Graggen et al., 1998).
Retinal ganglion cells (RGCs) in the mammalian vi-
sual system are of particular interest to neuroscientists
conducting studies of axonal regeneration after CNS in-
jury. The peripheral nerve (PN) bridging approach in vi-
sual system models has achieved success in promoting
RGC axonal regeneration (Richardson et al., 1980; So
and Aguayo, 1985). Recently, using this PN-grafting 
experimental paradigm, we showed that ciliary neu-
rotrophic factor (CNTF) significantly increased axonal
regeneration of axotomized RGCs in adult rodents (Cui
et al., 1999; 2003; Cui and Harvey, 2000). Although RGC
axonal outgrowth was enhanced by IN-1 treatment in
vitro (Bähr and Schwab, 1996) and in developing rats
(Weible et al., 1994), little is known about the effect of
IN-1 on the regeneration of RGC in adults. As Nogo has
been shown to express in the optic nerve (ON), ganglion
cell layer of the retina, and PN (Hunt et al., 2002), we
thought it would be interesting to see what effect IN-
1–producing hybridoma cells would have on adult rodent
RGC axonal regeneration when applied along PN grafts.
Because different sites of ON injury appear to have dif-
ferent effects on the extent of RGC loss and axon re-
generation (You et al., 2000), a phenomenon probably
owing to the presence of a differential amount of in-
hibitory molecules in ON stumps of different lengths, we
used both intracranial (distal) and intraorbital (proximal)
ON transection models in this study. We also used an in-
traorbital ON crush model to determine whether RGC ax-
ons could regenerate across the injury site into the distal
part of the ON, a hostile CNS environment. As CNTF
has been shown to promote RGC axon regeneration (Cui
et al., 1999, 2003), and combined application of neu-
rotrophin-3 and IN-1 antibody promotes long-distance
axon regeneration in spinal cord (Schnell et al., 1994), in
this study we used a combined approach of applying 
IN-1 hybridoma cells along the PN or ON and injecting
CNTF into the eyes.
MATERIALS AND METHODS
Young adult (6–8 weeks old; Mesocricetus auratus)
hamsters were used in the intracranial and intraorbital PN
graft models, while Sprague-Dawley (SD) rats were used
in the intraorbital ON crush model. All hamsters under-
went ON transection, and a 1.5-cm-long PN graft was at-
tached to the ON stump. The rats all underwent intraor-
bital ON crush. The experimental procedures for these
paradigms have been described elsewhere (Cui et al.,
1999, 2003; Yin et al., 2003). All surgical procedures
were carried out under Sagatal (sodium pentobarbitone,
60 mg/kg body wt) anesthesia in hamsters, and ketamine
(65 mg/kg body wt) and Xylazine (6.5 mg/kg body wt)
anesthesia in rats.
Intracranial PN Graft Experiments
For intracranial ON transection, a small hole was
drilled in the left frontal bone just rostral (1.5 mm) to the
bregma. Neural tissue below the craniotomy was re-
moved by aspiration to expose the left ON. A pair of
small scissors was used to completely transect the ON
(about 7 mm from the optic disc). A 1.5-cm-long seg-
ment of autologous peroneal branch of sciatic nerve was
obtained from the left leg, guided into the cranial cavity,
and apposed onto the proximal stump of the transected
ON (Fig. 1A). The connection of the PN graft with the
ON stump was maintained by packing the cavity with
pieces of Gelfoam. This approach has been shown to
maintain the PN-ON interface successfully (Lau et al.,
1994). The remaining portion of the PN (distal part) was
placed on top of the skull and secured to surrounding tis-
sue using 6/0 suture.
After the PN grafting procedure, animals were divided
into six groups. Group 1 (n 5 5), the control group, re-
ceived horseradish peroxidase (HRP) antibodies-produc-
ing hybridoma cells contained in filter paper capsules
(Ravioli). Group 2 (n 5 23) received IN-1 hybridoma
cells in Ravioli. Group 3 (n 5 10) received direct appli-
cation of IN-1 hybridoma cells soaked in Gelfoam and
daily intraperitoneal (i.p.) injection of immunosuppres-
sant cyclosporin-A (CsA) (1 mg/100 g/day) for 20 days.
Group 4 (n 5 5) received IN-1 hybridoma cells in Ravi-
oli and intravitreal injections of CNTF. To apply CNTF
intravitreally, a total of five injections (1 mg/mL 3 5) in
each animal were performed every 5 days, starting from
the day of axotomy. Group 5 (n 5 5) received HRP hy-
bridoma cells in Ravioli and a PN segment (2 mm) in the
eye. The final group (n 5 4) received IN-1 hybridoma
cells in Ravioli and a PN segment (2 mm) in the eye.
The biological activity of the HRP– or IN-1–produc-
ing hybridoma cells was tested in vitro before use. After
expanding the cells in modified ISCOVE’s medium 
containing 10% fetal calf serum, 2 mM L-glutamate, 100
U/mL penicillin, 100 mg/mL streptomycin sulfate, and
50 mM b-mercaptoethanol, cells were washed and then
centrifuged for 5 min. The supernatant was discarded and
the cells were resuspended in an appropriate concentra-
tion for injection into the Ravioli or direct application.
The Ravioli holding the hybridoma cells was made of 
filter paper. A Ravioli containing either 106 HRP or 106
IN-1 cells was implanted over the top of the intracranially
transected ON. Another Ravioli containing 5 3 105 of
the same cell type was also applied intraorbitally along
the dura-opened ON (Fig. 1A) to maximize the effect of
the antibody-producing cells. For the direct application
of the cells in Group 3, 106 IN-1 cells soaked in Gelfoam
were applied into the cranial cavity on top of the tran-
sected ON and PN graft.
Intraorbital PN Graft Experiments
To axotomize the ON intraorbitally, the ON was ac-
cessed through the dorsal opening of the orbit after ex-
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cision of the superior extraocular muscles. The dural
sheath of the ON was then opened with a 271/2-gauge
needle, and a pair of small scissors was used to com-
pletely transect the ON inside the dura at a distance of
about 1.5 mm from the optic disc. A 1.5-cm segment of
peroneal nerve was sutured (10/0) onto the axotomized
ON. The distal part of the PN graft was secured onto the
surrounding tissue on the skull. The animals were divided
into two groups (Table 1). Group 1 received 106 HRP
cells, and group 2 received 106 IN-1 cells intraorbitally,
both by means of a Ravioli application along the opened
ON (Fig. 1B).
Intraorbital ON Crush Experiments
To further test the effect of IN-1 on axonal regenera-
tion of RGCs, an intraorbital ON crush injury was per-
formed in adult rats. The ON was accessed through 
the same approach described above. A large proportion
of the ON dural sheath was then opened with a 271/2-
gauge needle for better penetration of the IN-1 antibod-
ies. A pair of fine forceps was used to completely crush
the ON inside the dura at a distance of about 1.5 mm
from the optic disc. Four groups of animals were studied
in this model. Group 1 (n 5 4) received intravitreal in-
jections of saline (Fig. 1C). Group 2 (n 5 5) received in-
travitreal injections of CNTF. Group 3 (n 5 5) received
IN-1 cells in Ravioli. Group 4 (n 5 5) received IN-1 cells
in Ravioli and intravitreal injections of CNTF (Fig. 1C).
As we had previously found that CNTF significantly en-
hanced the RGC axon regeneration of rodents in a dose-
dependent manner (Cui et al., 1999), four injections of
CNTF (2 mg each) were made at 5-day intervals, start-
ing from the day of axotomy, in the two groups treated
with CNTF.
Visualization of Regenerating RGCs
The animals were allowed to survive for 30 days in
the intracranial model and 20 days in the intraorbital
model. To retrogradely label regenerating RGCs, a piece
of Gelfoam soaked with 6% Fluoro-Gold (FG) was ap-
plied to the freshly cut distal end of the PN grafts (PN
graft paradigms). Animals were given 2 days for retro-
grade transport of the dye and subsequent labeling of 
the regenerating RGCs. Animals were then euthanized
with an overdose of Sagatal and perfused with 4%
paraformaldehyde. In rats (ON crush experiments), a new
transection was made on the crushed ON distal (2 mm)
to the crush site, and one or two 4DiI-10Asp (DiAsp)
crystals were placed at the newly transected site. In or-
der to limit the possible diffusion of the dye, animals were
allowed to survive only another 18 h, and the left retinas
were then removed and postfixed in the same fixative for
1 h. They were flat-mounted with 30% glycerin and ex-
amined under fluorescent microscope.
Statistical Analysis
For statistical analysis of the results, data in each ex-
periment were analyzed using one-way analysis of vari-
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FIG. 1. Experimental paradigms in this study. (A) Intracranial
ON axotomy and transplantation of a PN graft. Animals were
treated with either HRP cells or IN-1 cells, in Ravioli or applied
directly with i.p injections of CsA. In some animals, intravitreal
injections of CNTF or insertion of a PN segment were performed.
(B) Intraorbital ON axotomy and transplantation of a PN graft.
Animals were treated with HRP cells or IN-1 cells in Ravioli.
(C) Intraorbital ON crush model. Animals were treated with IN-
1 cells in Ravioli, CNTF in eye, or both treatments combined.
Saline-injected animals served as controls.
TABLE 1. AVERAGE NUMBERS OF REGENERATING RGCS
WITH STANDARD DEVIATION (SD) IN HAMSTERS
WITH INTRAORBITAL ON TRANSECTION AND
TRANSPLANTATION OF A PN GRAFT ONTO ON STUMP
No. animals Mean SD
HRP cells 3 4007 1192
IN-1 cells 3 4242 1153
ance (ANOVA) followed by Bonferroni tests for intra-
group comparisons (Cui et al., 1999, 2003). In the intra-
orbital PN graft experiment in which only two groups were
used, Student t test was used for comparison.
RESULTS
The eyes with multiple intravitreal injections showed
no obvious infections. The intraorbital ON axotomy pro-
cedure did not cause severe bleeding. A representative
fluorescence photomicrograph of FG-labeled regenerat-
ing RGCs in a retinal wholemount treated with CNTF in
the distal ON axotomy model is shown in Figure 2.
Intracranial PN Graft Experiments
The ability of RGCs to regenerate distally axotomized
axons in this study was poor. The average number of re-
generating RGCs in animals implanted with HRP cells
was 1.8/retina (Fig. 3). This value is not significantly 
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FIG. 2. A representative fluorescence photomicrograph of FG-labeled regenerating RGCs in a retinal wholemount treated with
CNTF in distal ON axotomy model. Three regenerating RGCs are seen in this field. Bar 5 40 mm.
FIG. 3. Experimental results (average numbers of regenerating RGCs and standard deviation) obtained from intracranial ON
axotomy plus PN graft model. Data for the empty bars had been published elsewhere (Cui et al., 1999) and were put here for
relevant comparisons. A synergistic effect of IN-1 and CNTF was observed. Statistical significant levels were indicated by *p ,
0.05, **p , 0.01, or ***p , 0.001.
different from our previous result in PN graft-only ani-
mals with the same experimental paradigm (mean 5
4.7/retina, Cui et al., 1999; p . 0.05, Bonferroni test).
Application of IN-1 cells in Ravioli or directly in
Gelfoam plus daily i.p. injections of immunosuppressant
CsA failed to increase the number of regenerating RGCs.
The numbers of regenerating RGCs in this paradigm were
4.7/retina and 11.8/retina, respectively (Fig. 3). Both are
not significantly different from the HRP cell control value
(p . 0.05, Bonferroni test).
When IN-1 cells were applied in Ravioli in conjunc-
tion with intravitreal injections of CNTF (1 mg 3 5), 
the number of regenerating RGCs was increased to
190/retina (Fig. 3). This value is significantly higher than
the HRP cell control value (p , 0.001, Bonferroni test;
Fig. 3). Compared with our previous CNTF applica-
tion–alone group of the same dosage and paradigm
(mean 5 120/retina, Cui et al., 1999), this value is also
significantly higher (p , 0.05, Bonferroni test; Fig. 3).
Application of HRP cells with a PN segment in eye
yielded a value of 40.2/retina (Fig. 3). This value is sig-
nificantly different from the HRP cell control at p , 0.05
(Bonferroni test) level (Fig. 3). When IN-1 cells were ap-
plied together with a PN segment in the eye, the number
of regenerating RGCs further increased to 63/retina (Fig.
3). While these two values from PN-treated eyes are not
significantly different from each other, the latter value is
higher than the HRP control at an even higher level of
significance (p , 0.01, Bonferroni test). These results
also indicate a synergistic effect of IN-1 and neurotrophic
factors released from the PN. In summary, treatment with
IN-1 cells alone failed to increase axon regeneration of
distally injured RGCs but it acted synergistically with in-
travitreal application of appropriate neurotrophic factor
to further increase the number of RGCs regenerating ax-
ons into PN grafts.
Intraorbital PN Graft Experiments
The capability of RGCs to regenerate is closely corre-
lated with the distance of the axonal injury site from the
cell bodies; in other words, the closer the injury site, the
higher the potential that the RGCs are able to regrow their
processes (You et al., 2000). Consistent with this obser-
vation, the number of regenerating RGCs in the proxi-
mal ON injury model was much higher than that in the
distal ON injury model. The average number of regener-
ating RGCs in intraorbitally transected animals treated
with HRP cells was 4007/retina (Table 1). Treatment with
IN-1 cells alone also failed to significantly increase the
number of regenerating RGCs in this model (p . 0.05,
Student t test) and yielded a mean value of only
4242/retina (Table 1).
Intraorbital ON Crush Experiments
Considering that the injured RGC axons may not re-
tract a significant distance into the proximal stump of the
transected ON, the presence of inhibitory molecules in
the part of the ON stump through which regenerating ax-
ons have to negotiate and extend into the PN grafts may
be low in the PN graft paradigms, and thus the effect of
IN-1 treatment would not be easily detected. To maxi-
mize the effect of IN-1 treatment, an ON crush model
was used to determine if IN-1 treatment would promote
the regeneration of injured RGC axons into the distal part
of the ON, a CNS environment known to contain high
amount of inhibitory molecules produced by the oligo-
dendrocytes.
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FIG. 4. Fluorescent image of longitudinal section of ON showing the limited diffusion of the fluorescent dye 4Di-10Asp at the
tip. Bar 5 100 mm.
Examination of cryosectioned ON after this short pe-
riod of labeling revealed limited diffusion of the dye, thus
avoiding dye contamination at the crush site and label-
ing of RGCs by diffusion (Fig. 4). In the control animals
with ON crush that received intravitreal injections of
saline, the number of RGCs that regenerated their axons
for at least 2 mm into the distal part of the crushed ON
was low, an average of 7.5/retina (n 5 6; Fig. 5). In-
travitreal injections of CNTF alone substantially in-
creased the number of regenerating RGCs in this group
(mean 5 114.9/retina, n 5 7; Fig. 5). Although there was
nearly a 15-fold increase, the increase failed to reach a
significant level (p . 0.05, Bonferroni test), owing to the
high variation in this CNTF treatment group (ranging
from 3 to 221/retina, SD 5 96; Fig. 5). However, when
the two extremely low values (3 and 11), suggestive of
poor intravitreal CNTF injections, were removed from
the data analysis, the average number of regenerating
RGCs in CNTF-treated group became significantly
higher (p , 0.05, Bonferroni test) than the saline control.
Note that previous studies have shown that intravitreal
injections of CNTF significantly increase the number of
regenerating RGCs in a PN graft (Cui et al., 1999).
Treatment with IN-1 hybridoma cells alone achieved
a 16-fold increase in the number of regenerating axons
in this model (mean 5 114/retina, n 5 5; Fig. 5). Again,
owing to the high variation in this group (ranging from
7 to 338/retina, Fig. 5), the increase failed to reach a 
statistically significant level (p . 0.05, Bonferroni test).
However, application of IN-1 cells in conjunction with
intravitreal injections of CNTF further increased the
number of regenerating RGCs. The average number of
regenerating RGCs in this condition was 517/retina (n 5
5; Fig. 5). This value is significantly higher than the saline
control value (p , 0.001, Bonferroni test; Fig. 5). In ad-
dition, this value is also significantly higher than both the
CNTF-alone treatment group and IN-1 cell–alone treat-
ment group (both p , 0.001, Bonferroni test; Fig. 5). In
summary, treatment with IN-1 cells also acted synergis-
tically with intravitreal application of CNTF to further
increase the number of RGCs that regrew axons into the
distal part of the ON.
DISCUSSION
In this study, we implanted IN-1 antibody–secreting
hybridoma cells along the pathway of the ON tract using
various approaches, such as applying the cells intracra-
nially and/or intraorbitally, in Ravioli or directly with im-
munosuppressant CsA injection, in intracranial or intra-
orbital injury models, and with or without intravitreal
injection of CNTF. IN-1 hybridoma cell treatment alone
failed to significantly enhance RGC axon regeneration
into a PN graft in both proximal and distal ON axotomy
models or into the distal part of crushed ON. However,
IN-1 treatment was found to act synergistically with in-
travitreal application of CNTF or a PN segment to sig-
nificantly promote the number of regenerating RGC 
axons. This is consistent with a previous report in 
which IN-1 acted synergistically with brain-derived neu-
rotrophic factor (BDNF) to further enhance the regrowth
of intracranially crushed RGC axons into the distal side
of the ON in developing rats (Weibel et al., 1994) or with
NT-3 to further promote the sprouting of corticospinal
tract after injury (Schnell et al., 1994).
Neurotrophins have been widely shown to enhance
axon regeneration in the CNS. Importantly, a recent study
showed that prior exposure of neurons to neurotrophins
made them insensitive to the inhibitory effect of myelin
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FIG. 5. Experimental results (average numbers of regenerating RGCs and standard deviation) obtained from the intraorbital
ON crush model. Statistical significant levels are indicated by ***p , 0.001.
substrates or MAG (Cai et al., 1999). It is known that
different neuronal populations have different specificities
in response to neurotrophic factors. In rodent visual sys-
tems, we found that CNTF, but not BDNF, NT-4/5, NT-
3, NGF, or bFGF, promoted RGC axon regeneration into
a PN graft (Cui et al., 1999; 2003), even though BDNF
and NT-4/5 enhanced RGC survival (Mey and Thanos,
1993; Cui et al., 2003). Although we failed to obtain sig-
nificantly higher number of RGCs regrowing axons into
the distal part of the ON after CNTF treatment, owing to
the high level of variation, CNTF may also act on RGCs
to overcome inhibitory molecules in a similar fashion as
we recently observed significant increase in growth-
associated protein-43 (GAP-43)–positive axons in the
ON of CNTF-treated rats (S.W. You et al., unpublished
observations). IN-1 antibody treatment has recently been
reported to upregulate the expression of BDNF, GAP-43,
and transcription factors STATs (Bareyre et al., 2002),
whose signal pathways may contribute to the enhanced
axonal regeneration. The observed synergistic effect of
IN-1 and CNTF in this study may be a result of IN-1’s
blockade of Nogo and upregulation of axon regeneration
signaling and CNTF’s ability to overcome of the in-
hibitory effect of other inhibitors such as myelin sub-
strates or MAG.
Although IN-1 promoted axonal regeneration and im-
proved functional recovery under various conditions in
at least some parts of the CNS (Thallmair et al., 1998;
Z’Graggen et al., 1998; Merkler et al., 2001), blockade
of Nogo alone caused only a small number of axons to
regrow. This is not surprising as blocking Nogo alone
will still allow other inhibitory molecules such as MAG
and OMgp to exert inhibitory effects, or scar tissue may
form a physical barrier for axons to pass. In addition, the
identification of differential Nogo receptor distributions
in different neurons and at different developmental ages
(Fournier et al., 2001) may explain the lack of action of
IN-1 antibodies in certain parts of the CNS (Oudega et
al., 2000).
A breakthrough was made recently in our understand-
ing of signaling transduction of these inhibitory mole-
cules. Nogo-A, MAG, and OMgp all act through the same
Nogo receptor, forming a receptor complex with p75 to
exert their inhibitory effects (Domeniconi et al., 2002;
Liu et al., 2002; Wang et al., 2002a,b; Wong et al., 2002).
However, a peptide that disrupts the interactions of Nogo
receptor with its ligands has been generated and shown
to promote robust sprouting of uninjured spinal cord tract
fibers, but only limited regeneration of fibers that are
damaged (GrandPre et al., 2002). These results further
confirm that, apart from Nogo-A, MAG, and OMgp,
other inhibitory factors such as amino-Nogo, proteogly-
can, tenascin, and scar tissue also play an important part
in impeding axon regrowth (Gates et al., 1996; Fawcett,
1997; David and Lacroix, 2003).
In the intraorbital PN graft model, injured axons might
not retract a significant distance into the ON stump, 
and thus the oligodendrocytes and myelin-associated in-
hibitory molecules through which regenerating RGCs
have to negotiate would be present only in a very small
portion (retraction distance) of the ON stump and at a
low level in the PN grafts. This low level of Nogo mol-
ecules may not render them as a dominant inhibitory fac-
tor, thus leading to the lack of effect of IN-1 treatment
in these conditions.
The less predominant role of oligodendrocyte- and
myelin-associated inhibitory molecules in axon regrowth
inhibition has been documented under various conditions.
Extensive axon regeneration has been seen in both nor-
mal and degenerating white matter tracts in the presence
of inhibitory molecules; however, regenerating axons
were stopped at the glial scar formation site in those stud-
ies (Davies et al., 1997, 1999). The role of chondroitin
sulfate-proteoglycans as the main inhibitory molecules in
scar tissue (Davies et al., 1999) and the subsequent degra-
dation of these molecules leading to enhanced axon re-
generation in spinal cord (Moon et al., 2001) have re-
cently been documented.
Recently, intrinsic axon regrowth capability has been
enhanced by cellular elevation of cAMP (Cai et al., 1999;
Qiu et al., 2002; Neumann et al., 2002). We also showed
that CNTF and cAMP elevation acted in concert to pro-
mote RGC axon regeneration (Cui et al., 2003). Thus
available information suggests that there may not be 
a single explanation for the failure of CNS axon regen-
eration, and any attempt to tackle the problem from a 
single aspect seems to fail. Combined experimental ap-
proaches, including neutralization of inhibitory mole-
cules (IN-1 or Nogo receptor blocker), blockade of in-
hibitory signaling pathways (Rho pathway inhibitor),
supplementation of appropriate neurotrophic factors 
(NT-3 or CNTF), provision of an environment suitable
for axon regeneration (PN graft or Schwann cell/olfac-
tory ensheathing glia transplantation), prevention of scar
tissue formation (Chondroitinase ABC), and elevation of
intrinsic regrowth capability (cAMP elevation) will be
necessary in any attempt to circumvent this devastating
condition (Cheng et al., 1996; Li et al., 1996; Lehmann
et al., 1999; Moon et al., 2001; GrandPre et al., 2002;
Qiu et al., 2002; Neumann et al., 2002; Cui et al., 2003).
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